To quantify the anti-emetic efficacy and adverse effects of cannabis used for chemotherapy-induced sickness.
extraction.
The following information were tabulated in the review: the characteristics of patients; chemotherapy regimen; active and control treatments; the number of patients; and relevant end points. Relative risks (RR) with 95% confidence intervals (CIs) were calculated for a difference between the cannabis and control treatments.
Methods of synthesis
How were the studies combined? The pooled RRs and 95% CI for cannabis versus control treatments were estimated using a fixed-effect model. The clinical relevance of the treatment effect was expressed as the number-needed-to-treat (NNT), along with 95% CIs.
How were differences between studies investigated? L'Abbe plots of event rates for nausea and vomiting were created for the control versus the cannabinoid-treated groups. A sensitivity analysis was conducted by separately analysing the data from active controlled trials with medium event rates (25 to 75%) and extreme event rates (less than 25% and greater than 75%) in control treatment groups. A doseresponse relationship was sought in the data from clinically homogeneous subgroups.
Results of the review
Thirty RCTs were included (1,760 patients were randomised but 394 patients were subsequently excluded by the original authors, leaving 1,366 evaluable patients).
The average sample size was 46 patients (range: 8 to 139).
Anti-emetic efficacy (10 RCTs).
There was wide variability in event rates with both cannabinoids and controls. The scatter in the event rates suggested increased efficacy with cannabinoids and relative homogeneity of the data.
Cannabinoids versus active control. Cannabinoids were more effective than active comparators for complete control of nausea (7 RCTs) and for complete control of vomiting (6 RCTs); the RRs were 1.38 (95% CI: 1.18, 1.62; NNT=6.4) and 1.28 (95% CI: 1.08, 1.51; NNT=8.0), respectively.
Cannabinoids versus placebo control. Cannabinoids were more effective than placebo for complete control of nausea (4 RCTs) and for complete control of vomiting (4 RCTs); the RRs were 1.21 (95% CI: 1.03, 1.42; NNT=8.0) and 1.84 (95% CI: 1.42, 2.38; NNT=3.3), respectively.
After the exclusion of studies in which the control groups showed extreme event rates (less than 25% or greater than 75%), cannabinoids were superior to conventional anti-emetics. The RRs for complete control of nausea and complete control of vomiting were 1.70 (95% CI: 1.32, 2.18; NNT=3.4) and 1.26 (95% CI: 1.07, 1.48; NNT=6.6), respectively.
After limiting the analysis to those trials with extreme event rates in the control group, there was no significant difference between cannabinoids and active comparators. These studies included one RCT that used low emetogenic drugs (vincristine and fluorouracil) and had low rates (less than 25%) of nausea in the control group, and 6 RCTs that had high rates (greater than 75%) of nausea in the placebo control groups. The latter 6 RCTs used regimes involving the following: high-dose methotrexate; doxorubicin and cytoxan; cisplatin; or a combination of cyclophosphamide, methotrexate and fluorouracil.
Patients' preference (18 crossover RCTs).
Significantly more patients expressed a preference to be treated with cannabinoids for further chemotherapy cycles rather than either placebo or active comparator. The RR versus placebo (4 RCTs) was 5.67 (95% CI: 3.95, 8.15; NNT=1.6) and the RR versus active control (14 RCTs) was 2.39 (95% CI: 2.05, 2.78; NNT=2.8).
Side-effects. Withdrawals due to side-effects were significantly more common with cannabinoids than with the control; the RR was 4.67 (95% CI: 3.07, 7.09; NNT=11).
Authors' conclusions
The cannabinoids tested in these trials may be useful as mood-enhancing adjuncts for controlling chemotherapy-related sickness in selected patients. Potentially serious side-effects, even when cannabinoids are taken orally or intramuscularly in the short term, are likely to limit their widespread use.
CRD commentary
The aims were stated and the inclusion criteria were defined in terms of the study design, intervention, participants and outcome. Several relevant sources were searched but different search strategies were mentioned in the abstract, the introduction and the methods section. Thus, it was difficult to ascertain which actual search strategy had been pursued.
The methods used to select the studies were described and no language restrictions were applied. It appears that no attempt was made to locate unpublished material, which raises the possibility of publication bias. The validity of the included studies was assessed using a validated scale and was reported in the tables. The methods used to assess validity were described. Relevant data were extracted and tabulated, but the methods used to extract the data were not reported. The studies were grouped by comparator and the data were combined in a meta-analysis. Heterogeneity of the results was assessed by plotting event rates in the control group against those in experimental treatment groups. A sensitivity analysis was performed to explore the influence of the event rate of the control group on the results. Side-effects and patients' preferences were both evaluated.
With the exception of the search strategy, this was a clearly written and presented review. The evidence presented supports the authors' conclusions.
Implications of the review for practice and research
Practice: The authors state that oral nabilone and dronabinol and intramuscular levonantradol are superior to conventional anti-emetics in chemotherapy, but that side-effects (some potentially beneficial and some harmful) are common with cannabinoids.
Research: The authors state that priority should be given to trials of cannabinoids for indications where there are few competing drugs, such as spasticity in multiple sclerosis. They also state that research is required to identify the patients who are most likely to benefit from the anti-emetic effect of cannabinoids, and who are least likely to suffer from neuropsychiatric adverse events. They suggest further trials in chemotherapy to establish the usefulness of cannabinoids as adjuncts to modern anti-emetics, using minimal effective doses.
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